Malignant Pleural Mesothelioma Market: Epidemiology, Therapies, and Key Companies - DelveInsight | Featuring Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche

Therapies for malignant pleural mesothelioma, including KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab), YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase combined with Pemetrexed and Cisplatin, MesoPher, and others, are anticipated to drive growth in the malignant pleural mesothelioma market in the coming years.

DelveInsight has released a new report titled "Malignant Pleural Mesothelioma - Market Insights, Epidemiology, and Market Forecast-2034," providing a comprehensive analysis of the disease, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Malignant Pleural Mesothelioma market report https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Malignant Pleural Mesothelioma Market Report:

The Malignant Pleural Mesothelioma (MPM) market is projected to experience steady growth between 2025 and 2034, driven by the emergence of novel therapies such as Volrustomig (MEDI5752), KEYTRUDA in combination with cisplatin/pemetrexed, Pegargiminase with pemetrexed and cisplatin, MesoPher, and Galinpepimut-S.
In September 2024, the FDA approved pembrolizumab (KEYTRUDA) combined with pemetrexed and platinum-based chemotherapy as a first-line treatment for unresectable advanced or metastatic MPM. This approval was based on results from the KEYNOTE-483 Phase 2/3 trial, which demonstrated improved overall survival (median OS: 17.3 vs. 16.1 months; HR 0.79, P = 0.0162) and a higher response rate (52% vs. 29%) compared to chemotherapy alone.
DelveInsight estimates that approximately 11,400 mesothelioma cases were reported across the 7MM in 2024, with a projected decline by 2034 at a negative CAGR of 0.3%. Despite the decrease in incidence, the MPM market value is expected to grow modestly, from around USD 210 million in 2024, with a forecasted CAGR of 0.7% during 2025-2034.
Key pharmaceutical companies in the MPM space include Bristol-Myers Squibb, Ono Pharmaceuticals, Merck, and Novocure, offering therapies such as OPDIVO (nivolumab) with YERVOY (ipilimumab), OPDIVO monotherapy, KEYTRUDA with pemetrexed, and the OPTUNE LUA device.
MPM remains challenging to diagnose due to non-specific symptoms and a long latency period, often resulting in late-stage detection. Although advanced imaging and biomarker research show potential, current diagnostic methods are limited, highlighting the urgent need for improved early detection strategies.
In 2024, the United States accounted for roughly 2,250 new MPM cases-about 20% of total incidence across the 7MM. In the EU4 and the UK, the disease was more prevalent in males, with approximately 5,000 cases compared to 1,400 in females, reflecting a clear gender disparity.
Additional companies evaluating new MPM therapies include Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, and Hoffmann-La Roche. Promising treatments in development include KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab) with YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase with pemetrexed and cisplatin, MesoPher, and others, indicating continued innovation in the MPM treatment landscape.
Malignant Pleural Mesothelioma Overview

Malignant Pleural Mesothelioma (MPM) is an aggressive cancer originating from the mesothelial cells of the pleura and is strongly linked to prolonged asbestos exposure. The disease progresses rapidly, carries a high mortality rate, and primarily affects older men, often developing decades after initial exposure. Significant tumor heterogeneity contributes to resistance to therapy, making management particularly challenging.

To improve diagnostic precision, the 2021 WHO Classification of Thoracic Tumors by IARC updated the terminology: "diffuse malignant pleural mesothelioma" was replaced with "diffuse pleural mesothelioma," and "localized malignant pleural mesothelioma" became "localized pleural mesothelioma."

Asbestos remains the main risk factor, with inhaled fibers causing chronic inflammation and cellular damage over many years. Additional contributors include exposure to minerals such as erionite, prior radiation therapy, and potential viral associations like simian virus 40. Genetic predispositions, especially BAP1 mutations, along with male sex and older age, also influence susceptibility.

Early-stage symptoms commonly include shortness of breath and chest pain, often due to pleural effusion, while tumor encasement of the lungs in advanced stages exacerbates these issues. Other signs such as fatigue, weight loss, and general malaise are typically driven by inflammatory cytokine release. Rare complications, including superior vena cava syndrome or difficulty swallowing, may arise if the tumor invades nearby structures. Some individuals may remain symptom-free for extended periods, underscoring the importance of regular monitoring in those with known asbestos exposure.

Malignant Pleural Mesothelioma Market Outlook

The treatment landscape for Malignant Pleural Mesothelioma (MPM) includes surgery, radiotherapy, and chemotherapy, with chemotherapy remaining the primary standard of care. Due to the aggressive nature of MPM, surgery is typically reserved for carefully selected patients, while radiotherapy is mainly employed to manage symptoms.

Common chemotherapy regimens include pemetrexed, cisplatin, gemcitabine, and carboplatin, which continue to be the most widely used treatments for the disease.

Chemotherapy for MPM is categorized into first-line and subsequent lines of therapy based on disease stage and prior treatment response. Despite the available options, each approach has limitations-surgery benefits only a small subset of patients, radiotherapy is not curative, and chemotherapy is often hampered by drug resistance and disease recurrence.

To overcome these challenges, several targeted therapies and immunotherapy agents have been approved, aiming to improve treatment outcomes and extend survival.

Nevertheless, there remains a significant need for more effective therapies, as current first-line treatments offer limited durability and variable efficacy across patients. Several promising investigational drugs are in development, including Volrustomig (MEDI5752), Pegargiminase combined with pemetrexed and cisplatin, and MesoPher. These emerging therapies provide potential for expanding and enhancing the treatment options available for MPM.

Discover how the Malignant Pleural Mesothelioma market is rising in the coming years @ https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=market&utm_campaign=kpr

Marketed Malignant Pleural Mesothelioma Drugs

KEYTRUDA (Pembrolizumab): Merck
OPDIVO (Nivolumab) and YERVOY (Ipilimumab): Bristol Myers Squibb/Ono Pharmaceuticals
OPDIVO (Nivolumab): Bristol Myers Squibb/Ono Pharmaceutical

Emerging Malignant Pleural Mesothelioma Drugs

Volrustomig (MEDI5752): AstraZeneca
Pegargiminase with Pemetrexed and Cisplatin: Polaris Pharmaceuticals
MesoPher: Amphera BV

Scope of the Malignant Pleural Mesothelioma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Malignant Pleural Mesothelioma Companies: Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others
Key Malignant Pleural Mesothelioma Therapies: KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab) and YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, and others
Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Malignant Pleural Mesothelioma Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement

To know what's more in our Malignant Pleural Mesothelioma report, visit https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=market&utm_campaign=kpr

Key benefits of the Malignant Pleural Mesothelioma Market Report:
Malignant Pleural Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Pleural Mesothelioma Epidemiology and Malignant Pleural Mesothelioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Malignant Pleural Mesothelioma market report provides insights into the current and emerging therapies.
The Malignant Pleural Mesothelioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Malignant Pleural Mesothelioma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Pleural Mesothelioma market.

Got queries? Click here to know more about the Malignant Pleural Mesothelioma market Landscape https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Malignant Pleural Mesothelioma Patient Share (%) Overview at a Glance
5. Malignant Pleural Mesothelioma Market Overview at a Glance
6. Malignant Pleural Mesothelioma Disease Background and Overview
7. Malignant Pleural Mesothelioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Malignant Pleural Mesothelioma
9. Malignant Pleural Mesothelioma Current Treatment and Medical Practices
10. Unmet Needs
11. Malignant Pleural Mesothelioma Emerging Therapies
12. Malignant Pleural Mesothelioma Market Outlook
13. Country-Wise Malignant Pleural Mesothelioma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Malignant Pleural Mesothelioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Malignant Pleural Mesothelioma Market Outlook 2034 https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=openpr&utm_medium=market&utm_campaign=kpr

Related Reports:

Malignant Pleural Mesothelioma Pipeline Insights, DelveInsight

"Malignant Pleural Mesothelioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Malignant Pleural Mesothelioma market. A detailed picture of the Malignant Pleural Mesothelioma pipeline landscape is provided, which includes the disease overview and Malignant Pleural Mesothelioma treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.